Teva Pharmaceuticals USA
Teva Pharmaceuticals USA
Explore linked clinical trials.6 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| The Mycophenolate Pregnancy Registry | autoimmune disease, immune system disorder | Recruiting | Not stated | 2026-10-06 | NCT01733082 | |
| Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental Disabilities | Dyskinesias, Neurobehavioral Manifestations, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, central nervous system disorder, developmental disability, drug-induced dyskinesia, intellectual disability, movement disorder, nervous system disorder, neurodevelopmental disorder, psychiatric disorder, tardive dyskinesia | Recruiting | Phase 4 | 2026-07-06 | NCT06997198 | |
| Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17 | Hemic and Lymphatic Diseases, Hodgkins lymphoma, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 2 | 2026-06-17 | NCT03755804 | |
| Antiretroviral Pregnancy Registry (APR): Multi-sponsor Registry to Detect Any Major Teratogenic Effect Involving Any of the Registry Drugs When Administered to Pregnant People. | Blood-Borne Infections, DNA Virus Infections, Digestive System Diseases, Genital Diseases, HIV infectious disease, Hepadnaviridae infectious disease, Infections, RNA Virus Infections, Urogenital Diseases, hepatitis, hepatitis B virus infection, immune system disorder, inborn error of immunity, infectious disease, lentivirus infection, liver disorder, sexually transmitted disease, uterine carcinosarcoma, viral hepatitis, viral infectious disease, viral sexually transmitted disease | Recruiting | Not stated | 2025-04-01 | NCT00404989 | |
| Expertise Asthma COPD Program with Digital Support | Hypersensitivity, Immediate, Respiratory Hypersensitivity, asthma, bronchial disorder, immune system disorder, lung disorder, obstructive lung disease, respiratory system disorder | Recruiting | Phase 3 | 2025-03-25 | NCT05831566 | |
| Reslizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study | Hypersensitivity, Immediate, Respiratory Hypersensitivity, asthma, bronchial disorder, immune system disorder, lung disorder, obstructive lung disease, respiratory system disorder | Recruiting | Phase 2 | 2017-09-14 | NCT02947945 |